Vivos Therapeutics Inc (VVOS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$0.10-7.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · VVOS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 48.4% |
Growth built into the price is above our model estimate.
The price assumes 138.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 43 industry peers
VVOS — dividend update
Dated 2026-10-15
Entry into a Material Definitive Agreement. Mutual Stock Purchase and Asset Exchange Agreement On October 14, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Mutual Stock Purchase and Asset Exchange Agreement (the “Agreement”) with SOD Sciences, Inc., a Florida corporation (“SOD”). SOD owns the ReBalU Protocol, a test/treat/retest platform, the architecture and related patent filings for a pseudohypoxia early-warning test (the “Test”), and has a marketin…
Why it matters: Nasdaq confirmed compliance with its $2.5 million equity rule. The next report will test if Vivos still meets it.
Worry ifThe next periodic report shows stockholders’ equity below $2.5 million. Or Nasdaq sends a new deficiency notice.
Less concerning ifThe next periodic report shows stockholders’ equity of at least $2.5 million. No new Nasdaq deficiency notice appears.
Why it matters: The AHA network could open access to more than 325,000 patients. Sales depend on signed deals and bankruptcy court approval.
Supportive ifVivos reports signed AHA marketing deals. The bankruptcy court approved the planned channel.
Worry ifVivos reports that the agreements were not signed, or the bankruptcy court rejects the plan.
Why it matters: Management tied the AHA plan to sleep testing revenue starting in 2027. Reported sales would show the channel is active.
Supportive ifVivos reports AHA-based sleep testing revenue in 2027 and gives a patient or test count.
Worry ifVivos reports no AHA-based testing revenue by the end of 2027, or says the launch was delayed.
Why it matters: Vivos owns half of the test, but sales depend on proof that it works and on its regulatory status.
Supportive ifVivos or SOD reports clinical results that support the test’s stated use. It names any needed regulatory clearance.
Worry ifA study does not support the test’s stated use. Or Vivos says validation or regulatory review blocks sales.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$286 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $932 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,604 loss on $10,000 · 96.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.